Clinical Trial Update: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating autologous SCG142 TCR T cells for HPV16/52-positive squamous cell carcinomas across multiple HPV-related sites; currently not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Squamous Cell Carcinoma
• Cervical Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Penile Squamous Cell Carcinoma
• Vaginal Squamous Cell Carcinoma
• Vulvar Squamous Cell Carcinoma

Drugs mentioned

• SCG142 TCR-T Cells (HPV-targeted T cell receptor-engineered T cells)

Snippet

Sponsor: SCG Cell Therapy Pte. Ltd. | Conditions: HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING